Sameer Jhavar (@sameerjhavar) profile picture

hi

Texas, USA
Joined March 2009
Sameer Jhavar retweeted
I forced a bot to read 1000 #internalmedicine personal statements & write its own. The syntax is a little off, but this bot has the template down! (Credit to @KeatonPatti's shtick.) #meded #match2019 Disclosures: I read every PS in detail, and I love interviewing applicants.
89
496
337
1,601
Sameer Jhavar retweeted
CONVERT Trial: Concurrent Chemoradiotherapy to Treat Elderly Patients With Limited-Stage SCLC ascopost.com/News/59480 #LCSM #oncology
Sameer Jhavar retweeted
Great day for oligometastatic disease! In a 24 hrs, 3 randomized trials demonstrate substantially improved survival in oligometastatic patients treated w/ consolidative RT. Lung: ow.ly/iMFX30mktYw prostate: ow.ly/NFbD30mktZX all tumor types: ow.ly/lC9H30mkucB
1
22
3
29
Sameer Jhavar retweeted
Exciting data from our NRG colleagues. Sets the tone for S1806. Congrats on a very nice trial. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Canc.. ncbi.nlm.nih.gov/pubmed/3043…
1
2
9
This, is a true golden nugget. @SFreedlandMD
just noticed this little tidbit...more men in the ProtecT trial for #pcsm died of 2nd malignancy in the surgery arm than the RT arm (not sig). Not saying RT-induced malignancies don't exist, just saying it's low enough not to be detectable in a trial of >1,000pts at 10yrs #radonc
3
9
19
Now in our Nov issue: previously presented at #ESMO2018 @myESMO: #Nivolumab plus #ipilimumab or nivolumab alone versus ipilimumab alone in advanced #melanoma (#CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial hubs.ly/H0fd60n0
1
19
2
34
No suggestion that cetuximab performed better in low risk subgroup in RTOG 1016, now published in @TheLancet nitter.cf/dr_jonathant/status/10… #radonc #hncsm
Were results specifically in “low risk” subgroup discussed? #radonc #hncsm
1
2
2
Replying to @Uroweb @F_Montorsi
Cancer specific survival was improved by MDT (sLND or SBRT) compared to SOC in PET detected nodal oligorecurrent PCa in retrospective matched-case analysis. Randomized survival data to be awaited from PEACE V(STORM) @AlbertoBreda1 @urosuardi @piet_ost @steuber #ERUS18
1
9
1
20
Sameer Jhavar retweeted
Dr. Palma presents the results of #SABR-COMET, a phase II RCT on #oligomets. Is this PFS benefit enough to treat? c @drdavidpalma #CAROCOMPCAMRT #RadOnc
7
13
7
29
Sameer Jhavar retweeted
Excellent editorial for POPSTAR trial by @piet_ost here - https://nitter.cf/t.co/dQ03CS6axV. #RadOnc @iurojc @EurUrolOncol #pcsm
Single session SABR for oligometastatic #prostatecancer : safe, feasible and effective in a prospective clinical trial buff.ly/2u4HxaO @_ShankarSiva